-17%

CJC-1295 + DAC 2 mg

Original price was: 29,99 €.Current price is: 24,99 €. with VAT

CJC-1295 + DAC is a GHRH analog with a Drug Affinity Complex group attached, which covalently binds it to albumin and extends its half-life to 6–8 days —compared to minutes for native GHRH. It is being studied in relation to growth hormone secretion, IGF-1 production, and body composition.

Purity ≥ 98% – Each batch verified by HPLC; COA available upon request
2 mg of lyophilized powder; stable for 24 months at −20 °C
Shipped within 48 hours

In stock

Dosage calculator

Quantity discount

Quantity	Price	% Discount
7+	22,49 €	10%
4+	23,74 €	5%

Category: Research on muscle growth

All products are sold exclusively for the purpose of scientific research and development.
The chemical substances may not be used as a medicine, drug, active substance, medical device, cosmetic product, substance for the manufacture of a cosmetic product, or as a substance for human consumption, i.e. as a food or nutritional supplement, or in any other similar way on humans or animals.

All customers MUST be at least 18 years of age to purchase our products.

Laboratory-tested

Fast and Discreet Shipping

Purity Guarantee

98%+

Description

CJC-1295 + DAC 2 mg – Long-Acting GHRH Analog (Research)

⚠️ Warning: CJC-1295 + DAC is intended exclusively for scientific and research purposes. It is not intended for human use as a medication, dietary supplement, or cosmetic product. Sale restricted to individuals 18 years of age or older.

What is CJC-1295 + DAC?

CJC-1295 + DAC is a synthetic analog of GHRH (Growth Hormone-Releasing Hormone) —a hormone that stimulates the pituitary gland in the human body to release growth hormone (GH). The abbreviation DAC stands for Drug Affinity Complex —a chemical modification that radically alters the pharmacokinetic profile of this molecule.
Structurally, it is a modified fragment of GHRH(1-29) with four amino acid substitutions (Ala→Aib, Arg→Lys, Gln→Ala, Cys34→Cys34) and an added maleimido-propionic acid (DAC) group at the C-terminus of the molecule. The molecular weight of CJC-1295 + DAC is 3,647 Da, which classifies it as a medium-sized peptide.
CJC-1295 + DAC is the subject of research primarily in the areas of growth hormone physiology, muscle tissue metabolism, and body composition. In preclinical protocols, it is used because of its significantly prolonged biological half-life compared to native GHRH or uncomplexed analogs.

The role of the DAC group: prolonging the biological half-life

Mechanism of binding to albumin

A key property of CJC-1295 + DAC is its ability to covalently bind to serum albumin in the bloodstream. This is facilitated by the DAC group (maleimido-propionic acid) at the C-terminus of the peptide, which reacts with the thiol groups of cysteine in the albumin molecule.
Albumin is the most abundant plasma protein (40–50 g/L in human blood), with a natural role as a carrier of hydrophobic molecules and a long biological half-life (approximately 19 days). By binding to albumin, CJC-1295 + DAC assumes its kinetic properties, thereby avoiding rapid degradation by endopeptidases and renal filtration.

Comparison of half-lives: native GHRH vs. CJC-1295 without DAC vs. CJC-1295 + DAC

Research data document a significant difference in the biological half-life among the various forms of GHRH analogs:

Compound	Biological half-life	GH secretion profile
Native GHRH	~7–10 minutes	Pulsatile, short-acting
Modified GRF 1-29 (CJC without DAC)	~30 minutes	Pulsatile, medium-length
CJC-1295 + DAC	6–8 days	Stable, long-term

This difference is crucial from a research perspective: while uncomplexed analogs simulate the physiological pulsatile secretion of GH, CJC-1295 + DAC maintains continuously elevated levels of GH and IGF-1 for several days.

Mechanism of Action in Research

Activation of GHRH receptors in the pituitary gland

CJC-1295 + DAC acts as a GHRH receptor (GHRHR) agonist on somatotrophic cells in the anterior lobe of the pituitary gland. By binding to GHRHR, it activates a signaling cascade via adenylate cyclase → increased intracellular cAMP concentration → PKA activation → expression and secretion of growth hormone (GH).
Due to the prolonged half-life of the DAC group, this axis undergoes long-term, non-pulsatile activation, which represents a distinct research model compared to other GHRH analogs.

Growth hormone secretion and IGF-1 production

Increased secretion of GH from the pituitary gland stimulates the liver to produce IGF-1 (Insulin-like Growth Factor 1) —a mediator through which GH exerts most of its anabolic and lipolytic effects in peripheral tissues.
In preclinical studies, rats administered CJC-1295 + DAC showed an increase in serum GH and IGF-1 levels that persisted throughout the observation period (5–12 days), confirming the compound’s long-term activity.
Source: Teichman SL et al., Journal of Clinical Endocrinology & Metabolism (2006)

Preclinical results: muscle mass and adipose tissue

In studies using animal models with chronic administration of CJC-1295 + DAC, researchers observed:- An increase in lean body mass compared to control groups – A reduction in the percentage of adipose tissue (both visceral and subcutaneous fat) with long-term administration – An increase in bone density in some protocols (preliminary data)
These results form the basis for further scientific research on the GH-GHRH axis in the context of body composition metabolism.

Comparison: CJC-1295 + DAC vs. Modified GRF 1-29

Property	CJC-1295 + DAC	Modified GRF 1-29 (CJC without DAC)
Biological half-life	6–8 days	~30 minutes
DAC Group	YES (albumin-binding)	NO
GH Secretion Profile	Stable, continuous	Pulsatile
Frequency Protocol (Research)	Once a week	1–2 times a day
MW	3,647 Da	3,370 Da
Research Application	Long-term studies of GH levels	Simulation of physiological pulsatility

The choice between CJC-1295 + DAC and Modified GRF 1-29 depends on the objectives of the research protocol. For studies requiring a stable, long-term elevation of GH/IGF-1, CJC-1295 + DAC is the standard choice.

Technical Specifications

Parameter	Value
Chemical Name	CJC-1295 + DAC (CJC-1295 with Drug Affinity Complex)
Form	GHRH analog with a C-terminal DAC group
Molecular weight	3,647 Da
Contents per package	2 mg
Purity	≥ 98% (HPLC-verified)
Product Form	Freeze-dried white powder
CAS Number	863288-34-0
Biological half-life	6–8 days (after binding to albumin)
Recommended storage conditions	−20 °C, protected from light and moisture
Stability (lyophilisate)	Up to 24 months at −20 °C
Stability (reconstituted)	Up to 14 days at 4 °C, up to 3 months at −20 °C
Intended Use	For scientific research purposes only

Frequently Asked Questions About CJC-1295 + DAC

What is DAC in CJC-1295 + DAC, and why is it important?

DAC (Drug Affinity Complex) is a chemical group attached to the C-terminus of the peptide that allows it to covalently bind to serum albumin in the bloodstream. Thanks to this bond, CJC-1295 + DAC “inherits” albumin’s long half-life (approximately 19 days), and its own effective half-life is extended to 6–8 days. This is a key pharmacokinetic difference compared to other GHRH analogs.

What is the difference between CJC-1295 + DAC and Modified GRF 1-29?

Both peptides are GHRH analogs and act on the same receptor. The main difference is their biological half-life: Modified GRF 1-29 (CJC without DAC) has a half-life of approximately 30 minutes and induces pulsatile GH secretion. CJC-1295 + DAC has a half-life of 6–8 days and maintains steadily elevated levels of GH and IGF-1. Therefore, Modified GRF 1-29 is used for research on physiological pulsatility, while CJC-1295 + DAC is used for studies of long-term GH elevation.

How should CJC-1295 + DAC be stored?

Store the lyophilized powder at −20 °C, protected from light and moisture. After reconstitution with bacteriostatic water, store at 4 °C (for up to 14 days) or refreeze at −20 °C (for up to 3 months). Before each research use, incubate the vial at room temperature for 5–10 minutes and gently swirl it—do not shake.

What is IGF-1, and what is its role in research on the GH axis?

IGF-1 (Insulin-like Growth Factor 1) is a peptide hormone produced by the liver in response to stimulation by growth hormone (GH). It mediates most of GH’s anabolic effects—including protein synthesis, cell proliferation, and lipolysis. In preclinical studies, serum IGF-1 levels are commonly used as a biomarker of GH axis activity, making it a key parameter measured in research on GHRH analogs.

Is CJC-1295 + DAC the same as CJC-1295?

In colloquial language, both peptides are referred to as “CJC-1295,” which causes terminological confusion. Technically, a distinction is made between: CJC-1295 + DAC (with Drug Affinity Complex, half-life 6–8 days) and Modified GRF 1-29 (also called CJC-1295 without DAC, half-life ~30 min). On jacked.sk, they are sold as separate products with precise labeling.

Is CJC-1295 + DAC legal in Slovakia?

CJC-1295 + DAC is not listed as a controlled substance in the EU. It is not approved as a drug, nor is it a dietary supplement or a cosmetic product. Its purchase for scientific and research purposes is legal in Slovakia. Jacked.sk sells CJC-1295 + DAC exclusively for scientific research purposes, not for human use.

⚠️ Warning – Intended exclusively for research purposes

All products sold on jacked.sk are intended EXCLUSIVELY for scientific research purposes. They are not intended for use as a medicine, drug, dietary supplement, or cosmetic product, nor for human or veterinary use. The results cited in the descriptions are based on preclinical studies (in vitro, animal models) and cannot be automatically extrapolated to human use. Sale restricted to individuals over the age of 18. By purchasing this product, the customer confirms that they are a professional researcher and will use the product solely in accordance with applicable laws.